Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.

Academic Article

Abstract

  • Prader-Willi syndrome (PWS) is a neurodevelopmental disorder caused by the absence of paternally expressed, imprinted genes on chromosome 15q11-13. Individuals with PWS characteristically have poor feeding and lack of appetite in infancy, followed by the development of weight gain and then uncontrolled appetite and lack of satiety, sometime after the age of two. The overwhelming drive to eat is coupled with reduced energy expenditure and decreased caloric requirements, thus, individuals with PWS will become severely obese unless their food intake is strictly controlled. The mechanisms underlying hyperphagia in PWS remain incompletely understood, and to date no drugs have proven effective in controlling appetite. However, clinical trials have started for several medications, which may provide therapeutic options for those with PWS. These medication trials may also provide insight into potential treatments for obesity in the general population. Ideally, these treatments will help alleviate the complex metabolic issues that are part of this syndrome.
  • Published In

  • Diseases  Journal
  • Keywords

  • Prader-Willi syndrome, drug trials, hyperphagia, obesity
  • Digital Object Identifier (doi)

    Author List

  • Miller JL; Strong TV; Heinemann J
  • Start Page

  • 78
  • End Page

  • 85
  • Volume

  • 3
  • Issue

  • 2